Market Research Report
Global CRO Market, 2016
|Published by||Frost & Sullivan||Product code||492746|
|Published||Content info||289 Pages
Delivery time: 1-2 business days
|Global CRO Market, 2016|
|Published: April 19, 2017||Content info: 289 Pages||
The Global CRO Market to Reach $64.58 Billion by 2021
The Global CRO Market, Forecast to 2021, presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides revenue forecasts for CROs globally by phase, therapeutic type and region. With the consolidation of the market as well as a higher cost and risk involved, the big companies are slowly shifting their business models towards a more collaborative business model and have started to look out for partners, giving rise to Bio analytics focused CROs.
The research study also addresses some of the major issues and challenges alongside providing information on the key unmet needs and emerging trends in the market. The report also outlines market drivers and restraints, market engineering measurements as well as R&D trends. Alongside the challenges and opportunities, a special focus is given on the emerging trends and their importance across the current and future market scenario. The report also highlights some of the major shifts occurring in the CRO and Pharma ecosystem with the emergence of several new and innovative CRO players in the market with a specific focus on niche segments, such as bioanalytics and HEOR amongst others.
Further to this, a detailed information will be provided on support services such as Central laboratory services, Bio analytics and Data management. The report covers the complete life cycle of CRO industry, starting from preclinical trials to post-marketing surveillance. One of the focus areas of this study would be bio analytics services, which is making a big impact in CRO industry. There is a major shift observed across the CRO landscape with several key pharma players now outsourcing their early drug development activities (pre-clinical and early phase research) to some of the leading CRO players in the market which was earlier handled by pharma companies themselves.
Some of the key questions being answered by this report include: